drugset / Trial / NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Timeline
- Start
- 2024-08-14
- Primary completion
- 2027-01-14
- Completion
- 2027-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CID-078 | Unknown | — | Oral |